Cell-based Immunotherapy
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
112
NCT01903330
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
Phase: Phase 2
Role: Lead Sponsor
Start: Mar 31, 2014
Completion: Jun 30, 2026
NCT05366062
ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab
Start: Jul 1, 2022
Completion: Jul 31, 2026
Loading map...